Japan’s Ministry of Health, Labour and Welfare (MHLW) has announced a reimbursement price for Eli Lilly’s Alzheimer’s disease drug Kisunla (donanemab), granting inclusion in the national health insurance (NHI) scheme and paving the way for launch, which the US firm said would take place on 26 November.
Japan Prices Kisunla Above Leqembi But May Cut In Future
Japan has granted an initial reimbursement price for Kisunla slightly above that for Alzheimer's rival Leqembi, but is holding out the prospect of future price revisions.
